-World's first predictive diagnostic test for diabetic kidney disease to be 
sold in Great Britain under distribution deal with global diagnostic 
distributor, Apacor Limited 
-Apacor will become the exclusive distributor for PromarkerD in Great Britain 
(England, Scotland and Wales) 
-Estimated 4.8 million people or seven per cent of the British population live 
with diabetes, according to Diabetes UK - these patients could benefit from 
regular PromarkerD testing 
-The UK's National Health Service (NHS) spends over £10 billion per year on 
diabetes, which is the equivalent to 10 per cent of its budget


Proteomics International Laboratories Ltd (Proteomics International; the 
Company; ASX: PIQ) announces it has today signed a distribution agreement with 
Apacor Limited to bring its PromarkerD test for diabetic kidney disease to 
patients in England, Scotland and Wales.

PromarkerD is a biomarker-based blood test that predicts renal (kidney) 
function decline in type 2 diabetes. Diabetic kidney disease (DKD) is a major 
complication arising from diabetes, and PromarkerD is the only available test 
capable of predicting the onset of the disease in patients with diabetes and no 
existing DKD.

The distribution agreement provides medical diagnostics company Apacor Limited 
with the right to sell the immunoassay version of the PromarkerD test. Apacor 
have 25 years of experience in medical and analytical diagnostics and 
specialise in bringing ground-breaking technologies to their customers. 
Importantly, Apacor have strong relationships with government and professional 
healthcare bodies across the UK, which the Company expects will prove 
invaluable for creating greater awareness and adoption of PromarkerD.

In the United Kingdom an estimated 4.8 million people, or seven per cent of the 
population, live with type 2 diabetes[1]. The UK's National Health Service 
spends at least £10 billion per year on diabetes; equivalent to 10 per cent of 
its budget. Eighty per cent of the cost of diabetes is spent treating 
complications such as DKD. The number of people living with diabetes in the UK 
is expected to rise to 5.3 million by 2025.

The early diagnosis of DKD using PromarkerD testing in diabetes can help inform 
doctors' treatment decisions to improve clinical outcomes for patients, and 
could drive improved therapeutic interventions. Reducing or delaying the 
progression of DKD and consequently the incidence of dialysis and kidney 
transplant would result in significant cost savings for health care systems.

Apacor managing director Anthony Bellm said he was excited about PromarkerD and 
being able to partner with Proteomics International to bring the test to the 
UK. 

"This world-first test offers huge benefits for the growing number of people 
living with diabetes in Great Britain, as well as significant savings to the 
NHS," he said. "The test will support doctors in providing early treatment 
options for high-risk patients, while avoiding unnecessary interventions for 
patients who are predicted to be at low risk of a decline in kidney function."

Proteomics International managing director Dr Richard Lipscombe said, "After 
extensive due diligence, we identified Apacor as a great partner for PromarkerD 
in Britain - they are well connected and we are already in contact with key 
bodies and opinion leaders to promote the test and bring PromarkerD into the 
clinic."

"The easy-to-use PromarkerD immunoassay platform allows hundreds of blood 
samples to be analysed quickly as part of a panel of routine blood tests and we 
expect this UK distribution deal to further drive global demand for the test," 
he said.

Proteomics International continues to target new markets for PromarkerD across 
multiple regions and is in advanced discussions with several major parties in 
other global jurisdictions.

About PromarkerD (www.PromarkerD.com)
Diabetic kidney disease (DKD) is a serious complication arising from diabetes 
which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a 
prognostic test that can predict future kidney function decline in patients 
with type 2 diabetes and no existing DKD. The patented PromarkerD test system 
uses a simple blood test to detect a unique 'fingerprint' of the early onset of 
the disease by measuring three serum protein biomarkers, combined with three 
routinely available conventional clinical variables (age, HDL-cholesterol and 
estimated glomerular filtration rate (eGFR)). A cloud based algorithm 
integrates the results into a patient risk report. In clinical studies 
published in leading journals PromarkerD correctly predicted up to 86% of 
otherwise healthy diabetics who went on to develop diabetic kidney disease 
within four years. The PromarkerD test is CE Mark registered in the European 
Union.

Further information is available through the PromarkerD web portal. 
To visit the PromarkerD virtual booth please see:  www.PromarkerD.com/product

[1] www.diabetes.org.uk

For further information, please contact: 
Proteomics International 
enquires@proteomics.com.au

SOURCE: Proteomics International